Physician profile
Maribel Cotto
NPI 1730348384
$22,456.35
in general payments reported to CMS, 2019-2025
55 companies · $2,755 in 2025
The $2,755 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,220 · 2020: $1,496 · 2021: $4,953 · 2022: $3,579 · 2023: $3,253 · 2024: $3,200 · 2025: $2,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,187 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,186.72 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,501.84 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $2,081.92 | 2019-2025 | Calquence, Lynparza, Tagrisso |
| Amgen INC. | $1,679.85 | 2019-2025 | Xgeva, Kyprolis, Lumakras |
| Novartis Pharmaceuticals Corporation | $1,409.48 | 2019-2025 | |
| Genentech USA, INC. | $1,383.53 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Pbg Puerto Rico LLC | $1,325.00 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,262.68 | 2019-2025 | Darzalex, Erleada, Imbruvica |
| Merck Sharp & Dohme LLC | $1,115.46 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Glaxosmithkline, LLC. | $962.59 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Eli Lilly Export S.A. Puerto Rico Branch | $925.98 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $586.36 | 2019-2025 | |
| Abbvie INC. | $534.11 | 2019-2025 | Venclexta, Epkinly |
| Puma Biotechnology, INC. | $440.32 | 2019-2025 | Nerlynx |
| Eisai INC. | $430.27 | 2019-2025 | |
| Incyte Corporation | $368.56 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $318.18 | 2019-2025 | Cabometyx |
| Pfizer INC. | $304.15 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $301.80 | 2019-2025 | Ninlaro |
| Seagen INC. | $253.10 | 2019-2023 | Tukysa |
| Clovis Oncology, INC. | $251.06 | 2019-2022 | |
| Celgene Corporation | $192.87 | 2019 | |
| Adc Therapeutics America, INC. | $183.55 | 2022-2023 | |
| Bayer Puerto Rico INC. | $181.14 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
| Astellas Pharma US INC | $173.98 | 2021-2025 | Xospata, Padcev, Vyloy |
| Janssen Biotech, INC. | $154.94 | 2019-2021 | |
| Sobi, INC | $146.57 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $144.77 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Taiho Oncology, INC. | $139.68 | 2019-2023 | |
| Gilead Sciences, INC. | $132.73 | 2022-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $123.49 | 2020-2022 | |
| Pfizer Pharmaceuticals LLC | $117.45 | 2019 | |
| Deciphera Pharmaceuticals INC. | $115.52 | 2023-2025 | Qinlock, Romvimza |
| Lantheus Medical Imaging, INC. | $111.46 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $105.97 | 2023-2025 | Libtayo, Lynozyfic |
| Alexion Pharmaceuticals, INC. | $94.84 | 2021-2023 | Ultomiris |
| Mirati Therapeutics, INC. | $92.91 | 2023-2024 | Krazati |
| Tempus Ai, INC | $90.21 | 2024-2025 | Xt Cdx |
| Springworks Therapeutics, INC. | $89.45 | 2024-2025 | Ogsiveo |
| Pharmaessentia USA Corporation | $72.80 | 2024 | Besremi |
| Genmab U.S., INC. | $72.29 | 2024 | Epkinly |
| Medtronic, INC. | $71.93 | 2024 | Micra |
| Beigene USA, INC. | $66.99 | 2023-2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $61.02 | 2022-2025 | |
| Lilly USA, LLC | $41.59 | 2020-2021 | |
| Caris Mpi, INC. | $38.42 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $30.60 | 2025 | Orserdu |
| Verity Pharmaceuticals INC. | $25.00 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $23.83 | 2019 | |
| Emd Serono, INC. | $22.45 | 2024 | |
| Foundation Medicine, INC. | $21.95 | 2023 | |
| Morphosys, US INC. | $21.36 | 2023 | Monjuvi |
| Fennec Pharmaceuticals, INC. | $21.07 | 2024 | Pedmark |
| Johnson and Johnson International | $16.81 | 2020 | |
| Blueprint Medicines Corporation | $15.22 | 2021 | |
| Array Biopharma INC | $5.25 | 2023 | Lorbrena, Mektovi, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maribel Cotto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.